Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2017

Open Access 01-12-2017 | Case report

Bacteremia caused by Bergeyella zoohelcum in an infective endocarditis patient: case report and review of literature

Authors: Yili Chen, Kang Liao, Lu Ai, Penghao Guo, Han Huang, Zhongwen Wu, Min Liu

Published in: BMC Infectious Diseases | Issue 1/2017

Login to get access

Abstract

Background

Bergeyella zoohelcum is an aerobic, Gram-negative bacterium that is frequently isolated from the upper respiratory tract of dogs, cats and other mammals. Clinically, B. zoohelcum has been reported causing cellulitis, tenosynovitis, leg abscess and septicemia, which is closely connected with animal bites. Here we describe a case of bacteremia in an infective endocarditis (IE) patient caused by B. zoohelcum, in China.

Case presentation

A 27-year-old infective endocarditis woman who had no history of dog bite nor other mammal exposure suffered bacteremia caused by B. zoohelcum. This patient, without evidence of polymicrobial infection, was treated with cefuroxime and had a good outcome.

Conclusions

B. zoolhelcum bacteremia is rarely reported in IE patients. Our report expands the range of known bacterial causes of infective endocarditis.
Literature
1.
Bailie WE, Stowe EC, Schmitt AM. Aerobic bacterial flora of oral and nasal fluids of canines with reference to bacteria associated with bites. J Clin Microbiol. 1978;7(2):223–31.PubMedPubMedCentral
2.
Talan DA, Citron DM, Abrahamian FM, Moran GJ, Goldstein EJ. Bacteriologic analysis of infected dog and cat bites. Emergency medicine animal bite infection study group. N Engl J Med. 1999;340(2):85–92.CrossRefPubMed
3.
Botha WC, Jooste PJ, Britz TJ. The taxonomic relationship of certain environmental flavobacteria to the genus Weeksella. J Appl Bacteriol. 1989;67(5):551–9.CrossRefPubMed
4.
Isotalo PA, Edgar D, Toye B. Polymicrobial tenosynovitis with Pasteurella multocida and other gram negative bacilli after a Siberian tiger bite. J Clin Pathol. 2000;53(11):871–2.CrossRefPubMedPubMedCentral
5.
Montejo M, Aguirrebengoa K, Ugalde J, Lopez L, Saez NJ, Hernandez JL. Bergeyella zoohelcum bacteremia after a dog bite. Clin Infect Dis. 2001;33(9):1608–9.CrossRefPubMed
6.
Reina J, Borrell N. Leg abscess caused by Weeksella zoohelcum following a dog bite. Clin Infect Dis. 1992;14(5):1162–3.CrossRefPubMed
7.
Shukla SK, Paustian DL, Stockwell PJ, Morey RE, Jordan JG, Levett PN, Frank DN, Reed KD. Isolation of a fastidious Bergeyella species associated with cellulitis after a cat bite and a phylogenetic comparison with Bergeyella zoohelcum strains. J Clin Microbiol. 2004;42(1):290–3.CrossRefPubMedPubMedCentral
8.
Beltran A, Bdiiwi S, Jani J, Recco RA, Go EE, Zaman MM. A case of Bergeyella zoohelcum bacteremia after ingestion of a dish prepared with goat blood. Clin Infect Dis. 2006;42(6):891–2.CrossRefPubMed
9.
Kallman O, Lundberg C, Wretlind B, Ortqvist A. Gram-negative bacteria from patients seeking medical advice in Stockholm after the tsunami catastrophe. Scand J Infect Dis. 2006;38(6–7):448–50.CrossRefPubMed
10.
Yi J, Humphries R, Doerr L, Jerris RC, Westblade LF. Bergeyella zoohelcum associated with Abscess and Cellulitis after a dog bite. Pediatr Infect Dis J. 2016;35(2):214–6.CrossRefPubMed
11.
Clinical and Laboratory Standards Institute. Interpretive criteria for identification of bacteria and fungi by DNA target sequencing: approved guideline. MM18-a. Wayne: Clinical and Laboratory Standards Institute; 2008.
12.
Vandamme P, Segers P, Vancanneyt M, van Hove K, Mutters R, Hommez J, Dewhirst F, Paster B, Kersters K, Falsen E, et al. Ornithobacterium rhinotracheale gen. Nov., sp. nov., isolated from the avian respiratory tract. Int J Syst Bacteriol. 1994;44(1):24–37.CrossRefPubMed
13.
Holmes B, Steigerwalt AG, Weaver RE, Brenner DJ. Weeksella zoohelcum sp. nov. (formerly group IIj) from human clinical specimens. Syst Appl Microbiol. 1986;8(3):191–6.
14.
Saphir DA, Carter GR. Gingival flora of the dog with special reference to bacteria associated with bites. J Clin Microbiol. 1976;3(3):344–9.PubMedPubMedCentral
15.
Lin WR, Chen YS, Liu YC. Cellulitis and bacteremia caused by Bergeyella zoohelcum. J Formos Med Assoc. 2007;106(7):573–6.CrossRefPubMed
16.
Sohn KM, Huh K, Baek JY, Kim YS, Kang CI, Peck KR, Lee NY, Song JH, Ko KS, Chung DR. A new causative bacteria of infective endocarditis, Bergeyella cardium sp. nov. Diagn Microbiol Infect Dis. 2015;81(3):213–6.CrossRefPubMed
17.
Vaneechoutte M, Dijkshoorn L, Nemec A, et al. Acinetobacter, Chryseobacterium, Moraxella, and other nonfermentative gram-negative rods. In: Versalovic J, Carroll KC, Jorgensen JH, et al., editors. Manual of clinical microbiology, vol. 1. 10th ed. Washington, DC: ASM Press; 2011. p. 714–38.CrossRef
18.
Noell F, Gorce MF, Garde C, Bizet C. Isolation of Weeksella zoohelcum in septicaemia. Lancet. 1989;2(8658):332.CrossRefPubMed
19.
Kivinen PK, Lahtinen MR, Ruotsalainen E, Harvima IT, Katila ML. Bergeyella zoohelcum septicaemia of a patient suffering from severe skin infection. Acta Derm Venereol. 2003;83(1):74–5.PubMed
Metadata
Title
Bacteremia caused by Bergeyella zoohelcum in an infective endocarditis patient: case report and review of literature
Authors
Yili Chen
Kang Liao
Lu Ai
Penghao Guo
Han Huang
Zhongwen Wu
Min Liu
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2017
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-017-2391-z

Other articles of this Issue 1/2017

BMC Infectious Diseases 1/2017 Go to the issue

Research article

HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects

Research article

Pneumococcal carriage and antibiotic susceptibility patterns from two cross-sectional colonization surveys among children aged <5 years prior to the introduction of 10-valent pneumococcal conjugate vaccine — Kenya, 2009–2010

Research article

Hepatitis B vaccination coverage among healthcare workers at national hospital in Tanzania: how much, who and why?

Study protocol

Influenza and respiratory syncytial virus in infants study (IRIS) of hospitalized and non-ill infants aged <1 year in four countries: study design and methods

Research article

Evaluation of candidemia in epidemiology and risk factors among cancer patients in a cancer center of China: an 8-year case-control study

Research article

Genetic variation in the microsomal triglyceride transfer protein (−493G/T) is associated with hepatic steatosis in patients infected with hepatitis C virus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits